- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02239952
HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)
October 6, 2020 updated by: M.E. van Linde, Amsterdam UMC, location VUmc
Pilot Study on the Determination of Tumor Concentrations of Protein Kinase Inhibitors in Patients With Newly Diagnosed High-grade Glioma
The purpose of this study is to determine intratumoral concentration of kinase inhibitors upon 2 weeks of treatment in tumor tissue (in the brain) of patients with high-grade gliomas (HGG).
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
In clinical trials for HGG, multiple agents targeting various oncogenic signaling pathways that play an important role in the biology of HGG have been studied, but unfortunately only a small number of patients seem to benefit from these treatment strategies.
Whether these disappointing results are due to a restricted drug delivery through the blood-brain barrier, or due to differential biological characteristics of these HGGs, remains unknown.
To better understand these clinical observations and to find potential insight how to overcome them, we intend to measure tumor concentrations of PKIs after approximately two weeks treatment and to determine whether these tumor concentrations correlate with plasma- and CSF concentrations of PKIs.
Subsequently, we intend to determine the (phospho)proteomic profiles and kinase inhibitory activity in tumor tissue from these HGG patients after approximately two weeks of treatment with a PKI.
Study Type
Interventional
Enrollment (Anticipated)
15
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: M.E. Van Linde, MD
- Phone Number: +31 (0)20 4444321
- Email: dm-onc@vumc.nl
Study Locations
-
-
Noord-Holland
-
Amsterdam, Noord-Holland, Netherlands, 1081 HV
- Recruiting
- VU University Medical Center
-
Contact:
- M.E. Van Linde, MD
- Phone Number: +31 (0)20 4444321
- Email: dm-onc@vumc.nl
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients without a history of brain tumor
- Initial brain MR-scan suggesting a high grade glioma, according to the interpretation of an expert neuroradiologist
- On initial MR-scan a tumor localisation that is deemed resectable without major neurological deficits
- Patients must have a Karnofsky Performance Score ≥ 70%
- Patients must have a RTOG Neurologic Function Status of 0-2
- Patients need to have adequate hematological, renal and hepatic function as assessed by the following laboratory requirements to be conducted within seven days prior to start study treatment: - Hemoglobin > 7.0 mmol/l - Absolute neutrophil count (ANC) >1,5 x 10*9/l - Platelet count > 100 x 10*9/l - ALT and AST< 2.5 x ULN - Alkaline phosphatase < 4 x ULN - Serum creatinine eGFR > 50 ml/min
- Patients are 18 years of older
- Male and female patients with reproductive potential must use an approved contraceptive method during and for three months after discontinuation of study treatment
- Patients need to give informed consent
- Patients should be able to swallow oral medication
Exclusion Criteria:
- Patients receiving prior chemotherapy, radiotherapy or anti-angiogenic therapy
- Use of anti-coagulant therapy
- Use of CYP3A4 enzyme-inducing drugs, other than dexamethasone (including Carbamazepine, Phenytoine, Phenobarbital)
- Initial MR-scan of the brain showing tumor hemorrhage or intracerebral hemorrhage
- Patients with progressive neurological symptoms despite dexamethasone
- Inability to comply with protocol or study procedures
- Pregnancy
- Patients with uncontrolled arterial hypertension. Blood pressure must be ≤160/95 mmHg at the time of screening on a stable antihypertensive regimen.
- Patients with a history of cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)
- Patients with evidence or history of bleeding diathesis
- Patients with a history of venous or arterial thrombo-embolic events or hemorrhagic disease during the past six months
- Patients with a history of congestive heart failure (NYHA III, IV)
- Patients with a history of peripheral vascular disease (Fontaine stage III and IV)
- Patients with stroke or myocardial infarction during the past six months
- Patients with a history of a recent peptic ulcer disease (endoscopically-proven gastric ulcer, duodenal ulcer of esophageal ulcer) during the past six months
- Patients with uncontrolled infections (> grade 2 NCI-CTC version 4.0)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Erlotinib
|
150 mg, once daily, oral use for 14 days
|
Experimental: sunitinib
|
50 mg once daily, oral use for 14 days
|
Experimental: vandetanib
|
300 mg, once daily, oral use for 14 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PKI and active metabolites concentrations in tumor tissue
Time Frame: 2 weeks
|
PKI concentrations and active metabolites in tumor tissue after approximately two weeks of PKI treatment will be determined.
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation of PKI and active metabolites concentrations in tumor.
Time Frame: 2 weeks
|
Venous blood sampling will be performed to determine plasma drug and active metabolites concentrations after approximately one and two weeks of PKI treatment and during surgery.
CSF samples will be drawn during surgery.
Plasma- and CSF drug concentrations will be correlated to tumor drug concentrations.
Plasma samples for pharmacodynamics will be simultaneously drawn with the on- and after treatment hematology and chemistry analysis.
|
2 weeks
|
Feasibility of determining the (phospho)proteomic profiles and kinase activity profiles in tumor tissue and CSF.
Time Frame: 2 weeks
|
Kinome wide and quantitative (phospho)proteomic profiles will be determined in tumor tissue of study patients and in tumor tissue of matched controled patients.
We anticipate that these profiles will reveal information on the effect of treatment on kinase abundances, phosphopeptide levels and on phosphorylation sites.
Differences in levels of phosphopeptides and fold-change of phosphorylation sites will be quantified.
In an exploratory design, we will determine whether observed profile differences can be correlated to drug concentrations in tumor tissue.
Kinase inhibition profiles will be measured according to standard methods as developed and modified in our laboratory.
|
2 weeks
|
Significant difference of the (phospho)proteomic profiles and kinase activities of tumor tissue in study patients and control group.
Time Frame: 2 weeks
|
The (phospho)proteomic profiles and kinase activity profiles will be determined in tumor tissue of study patients and in tumor tissue of patients in a control group. Kinase inhibition profiles will be measured according to standard methods as developed and modified in our laboratory. |
2 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2014
Primary Completion (Anticipated)
November 1, 2021
Study Completion (Anticipated)
November 1, 2021
Study Registration Dates
First Submitted
August 28, 2014
First Submitted That Met QC Criteria
September 11, 2014
First Posted (Estimate)
September 15, 2014
Study Record Updates
Last Update Posted (Actual)
October 8, 2020
Last Update Submitted That Met QC Criteria
October 6, 2020
Last Verified
October 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Erlotinib Hydrochloride
- Sunitinib
Other Study ID Numbers
- 2013.465
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on Sunitinib
-
AGO Study GroupPhilipps University Marburg Medical Center; HSK Reasearch GmbH WiesbadenCompletedPlatinum Refractory Epithelial Ovarian Cancer | Primary Cancer of the Peritoneum | Cancer of the Fallopian TubeGermany
-
Mothaffar RimawiTerminated
-
Cogent Biosciences, Inc.RecruitingMetastatic Cancer | Advanced Gastrointestinal Stromal TumorsUnited States, Korea, Republic of, Spain, United Kingdom, Australia, France, Italy, Netherlands, Taiwan, Germany, Denmark, Hong Kong, Canada, Sweden, Norway, Mexico, Czechia, Argentina, Hungary, Brazil, Chile, Poland
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedKidney CancerUnited States
-
PfizerCompletedBreast NeoplasmsUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
PfizerCompletedGastrointestinal Stromal TumorsKorea, Republic of
-
California Pacific Medical Center Research InstitutePfizer; University of California, San FranciscoCompleted
-
PfizerCompletedGastrointestinal Stromal TumorsUnited States, Czechia, France
-
Asan Medical CenterCompletedMetastatic Renal Cell CarcinomaKorea, Republic of